Get the Stockscreener App
114.22
109.08%
59.59
After Hours:
115.75
1.53
+1.34%
Corcept Therapeutics Inc stock is traded at $114.22, with a volume of 14.30M.
It is up +109.08% in the last 24 hours and up +88.54% over the past month.
See More
Previous Close:
$54.63
Open:
$94.93
24h Volume:
14.30M
Relative Volume:
12.80
Market Cap:
$5.94B
Revenue:
$628.56M
Net Income/Loss:
$141.82M
P/E Ratio:
90.65
EPS:
1.26
Net Cash Flow:
$142.60M
1W Performance:
+92.06%
1M Performance:
+88.54%
6M Performance:
+146.80%
1Y Performance:
+353.43%
1-Day Range:
$87.58
$117.33
1-Week Range:
$53.79
$117.33
52-Week Range:
$20.84
$117.33
Corcept Therapeutics Inc Stock (CORT) Company Profile
Name
Corcept Therapeutics Inc
Sector
Industry
Phone
650.688.8803
Address
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
114.22 | 5.94B | 628.56M | 141.82M | 142.60M | 1.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-23 | Upgrade | Truist | Hold → Buy |
| Apr-11-23 | Initiated | SVB Securities | Market Perform |
| Apr-04-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-01-22 | Downgrade | Truist | Buy → Hold |
| Jul-27-22 | Upgrade | Jefferies | Hold → Buy |
| Jun-27-22 | Resumed | Canaccord Genuity | Buy |
| Feb-02-22 | Initiated | Canaccord Genuity | Buy |
| Jan-28-22 | Initiated | Truist | Buy |
| Aug-05-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-24-19 | Initiated | Jefferies | Buy |
| Sep-06-19 | Initiated | H.C. Wainwright | Buy |
| Feb-04-19 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-10-18 | Reiterated | Stifel | Hold |
| May-31-18 | Downgrade | Stifel | Buy → Hold |
| Mar-09-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Aug-31-17 | Initiated | Stifel | Buy |
| Feb-02-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-21-15 | Initiated | FBR Capital | Outperform |
| Jan-13-14 | Downgrade | Stifel | Buy → Hold |
| Aug-09-13 | Downgrade | Janney | Buy → Neutral |
| Aug-09-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Feb-21-12 | Reiterated | JMP Securities | Mkt Outperform |
| Jan-06-10 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-17-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jun-21-07 | Upgrade | Punk, Ziegel & Co | Mkt Perform → Accumulate |
View All
Corcept Therapeutics Inc Stock (CORT) Latest News
Corcept looks to NDA following strong phase III ovarian cancer data - BioWorld MedTech
Corcept’s Relacorilant Shows Benefit In Ovarian Cancer, Expanding Pipeline Opportunity - insights.citeline.com
Deep Dive Into Corcept Therapeutics Stock: Analyst Perspectives (7 Ratings) - Benzinga
Corcept Therapeutics Stock Jumps On Upbeat Ovarian Cancer Trial Data, Analysts Boost Price Forecast - Benzinga
Why Is Corcept (CORT) Stock Soaring Today - Yahoo Finance
Corcept’s ovarian cancer drug cuts disease progression in study, shares jump By Reuters - Investing.com
Corcept Therapeutics (NasdaqCM:CORT) Reports Positive Phase 3 Results Despite 8% Share Price Dip - simplywall.st
Corcept's ovarian cancer drug cuts disease progression in study, shares jump - Reuters
NewsMax, Celsius Holdings, Corcept Therapeutics: Market Minute - Yahoo Finance
Corcept shares soar after Phase 3 win in platinum-resistant ovarian cancer - Endpoints News
Corcept Therapeutics's Options Frenzy: What You Need to Know - Benzinga
Corcept Therapeutics shares surge on positive late-stage ovarian cancer trial results - Proactive Investors
Dow Gains Over 100 Points; NewGenIvf Group Shares Plummet - Benzinga
Yum Brands, Corcept Therapeutics, Hut 8: Trending tickers - Yahoo Finance
Market movers: Mr Cooper, Newsmax, Corcept Therapeutics... - Proactive financial news
HC Wainwright Adjusts Price Target on Corcept Therapeutics to $150 From $115, Maintains Buy Rating - MarketScreener
Corcept Therapeutics stock soars to all-time high of $95.42 - Investing.com
Corcept soars as ovarian cancer drug succeeds late-stage trial - TradingView
Sector Update: Health Care - TradingView
Corcept Therapeutics' Ovarian Cancer Therapy Meets Main Goal in Phase 3 Study; Shares Jump - Marketscreener.com
Corcept's ovarian cancer drug meets main goal in late-stage study, shares jump - TradingView
Corcept Therapeutics stock soars after successful Phase 3 trial - Investing.com
Corcept Therapeutics stock soars after successful Phase 3 trial By Investing.com - Investing.com UK
Corcept Therapeutics Says Primary Endpoint Met in Phase 3 Ovarian Cancer Drug Study; Shares Up Pre-Bell - MarketScreener
Corcept's ovarian cancer combination drug meets main goal in late-stage study - TradingView
Corcept reports key trial success in ovarian cancer treatment - Investing.com
Major Clinical Trial Success: New Ovarian Cancer Drug Shows 4.5-Month Survival Advantage - Stock Titan
Did Corcept Therapeutics Incorporated Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky InvestigateCORT - ACCESS Newswire
NewMax goes public, Corcept Therapeutics gains, Moderna under pressure - Yahoo Finance
Why Is Corcept (CORT) Down 5.3% Since Last Earnings Report? - Yahoo Finance
Corcept Therapeutics president Sean Maduck sells $102,804 in stock By Investing.com - Investing.com South Africa
Corcept therapeutics officer sells shares worth $25,504 - Investing.com India
Corcept therapeutics CEO Joseph Belanoff sells $120k in stock - Investing.com India
Corcept Therapeutics president Sean Maduck sells $102,804 in stock - Investing.com
3 Reasons to Sell CORT and 1 Stock to Buy Instead - Yahoo Finance
Avantax Advisory Services Inc. Invests $293,000 in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Global Cushing's Syndrome Treatment Market: Research & - openPR
Corcept Therapeutics Incorporated (NASDAQ:CORT) Stake Raised by Natixis Advisors LLC - Defense World
Cushing's Syndrome Pipeline 2025: Therapies, MOA Insights, - openPR
Research Analysts Offer Predictions for CORT Q1 Earnings - Defense World
Is Corcept Therapeutics (CORT) Stock Outpacing Its Medical Peers This Year? - Yahoo
Raymond James Financial Inc. Makes New $12.08 Million Investment in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Proficio Capital Partners LLC Takes $1.60 Million Position in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Shareholders that lost money on Corcept Therapeutics Incorporated(CORT) should contact Levi & Korsinsky about Securities Fraud InvestigationCORT - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics IncorporatedCORT - PR Newswire
Victory Capital Management Inc. Increases Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
Charles Schwab Investment Management Inc. Acquires 25,073 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Defense World
M&T Bank Corp Sells 1,249 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) - Armenian Reporter
Corcept therapeutics director sells $117,920 in stock - Investing.com India
Corcept therapeutics director sells $117,920 in stock By Investing.com - Investing.com South Africa
Corcept trial to evaluate Cushing’s and hypertension - Cushing's Disease News
Corcept Therapeutics Inc Stock (CORT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.05%
1.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):